Mazdutide: A New Hope for Metabolic Disease Treatment
Mazdutide, with the research code IBI362, is an innovative drug jointly developed (Innovent Biologics) and Eli Lilly and Company. As a dual agonist of the glucagon (GCG) and glucagon - like peptide - 1 (GLP - 1) receptors, it has attracted significant attention in the field of metabolic disease treatment.
Mechanism of Action
Both GLP - 1 and GCG play crucial roles in human metabolic regulation. GLP - 1 is a hormone secreted by intestinal L cells, which is released after eating. It can act on multiple targets to regulate blood glucose and energy metabolism. On the one hand, GLP - 1 can stimulate insulin secretion. Insulin, a key hormone for blood glucose regulation, promotes the uptake and utilization of glucose by cells, thereby reducing blood glucose levels. On the other hand, GLP - 1 inhibits the release of glucagon. Since glucagon raises blood glucose levels, its inhibition reduces the output of glucose from the liver, further stabilizing blood glucose. Additionally, GLP - 1 delays gastric emptying, prolonging the retention time of food in the stomach and allowing it to be absorbed slowly in the small intestine, preventing rapid increases in blood glucose. It also acts on the appetite center in the brain, creating a feeling of satiety and reducing food intake.
GCG is mainly secreted by α - cells in the pancreas. When blood glucose levels drop, the release of GCG increases. It acts on the liver, promoting the breakdown of liver glycogen into glucose, which is then released into the bloodstream to raise blood glucose. At the same time, GCG promotes fat breakdown, converting fat into fatty acids and glycerol, which are released into the bloodstream. Fatty acids can be used by other tissues to generate energy, thus increasing energy consumption.
The uniqueness of Mazdutide lies in its ability to activate both GLP - 1 and GCG receptors simultaneously. When Mazdutide binds to the GLP - 1 receptor, it mimics the physiological effects of GLP - 1, suppressing appetite and reducing food intake to control calorie intake at the source. When it binds to the GCG receptor, it promotes fat breakdown, especially in the liver, increasing energy expenditure and accelerating fat burning. This synergistic effect of the dual - target mechanism achieves a "1 + 1 > 2" result, making it more advantageous than single - target drugs in weight loss and metabolic improvement.
Clinical Efficacy
1. Remarkable Weight - Loss Effect
The GLORY - 1 Phase III clinical trial fully demonstrated the outstanding weight - loss ability of Mazdutide. A total of 610 Chinese overweight or obese subjects were enrolled in this trial and randomly assigned to the Mazdutide 4mg group, 6mg group, and placebo group. They received subcutaneousonce a week for 48 weeks.
At week 32, the average body weight in the 4mg Mazdutide group decreased by 10.09% compared to the baseline, and the 6mg group decreased by 12.55%, while the placebo group only decreased by 0.45%. By week 48, the body weight in the 4mg group decreased by 11.00% from the baseline, the 6mg group decreased by 14.01%, and the placebo group decreased by only 0.30%. Meanwhile, the proportion of participants in the 6mg group who achieved at least a 15% reduction in body weight was 49.5%, significantly higher than that in the placebo group. This indicates that patients treated with Mazdutide experienced significant weight loss, and nearly half of the patients using the 6mg dose lost more than 15% of their body weight. For obese patients, such weight - loss results are highly significant.
2. Improvement of Metabolic Indicators
In addition to weight loss, Mazdutide also has a significant effect on improving metabolic indicators. Clinical studies have found that after using Mazdutide, patients' multiple cardiovascular and metabolic risk indicators were significantly reduced, including systolic blood pressure, triglycerides, low - density lipoprotein cholesterol (LDL - C, "bad cholesterol"), and uric acid. For example, the average reduction in systolic blood pressure effectively reduces the burden on the heart. The decrease in triglycerides reduces the lipid content in the blood, lowering the risk of cardiovascular diseases such as atherosclerosis. The reduction in LDL - C helps protect blood vessel health, and the decrease in uric acid levels also reduces the risk of diseases like gout.
For subjects with a high baseline liver fat content, the average reduction in liver fat content in the Mazdutide 6mg group was as high as 80.24%. This shows that it can effectively improve liver fat metabolism, reduce fat accumulation in the liver, which is of great significance for patients with fatty liver. It can relieve the burden on the liver and improve liver function.
Safety and Tolerability
In the Phase II clinical trial, Mazdutide showed good tolerability. The most common adverse reactions were mild to moderate gastrointestinal reactions, such as nausea, vomiting, and diarrhea. However, these adverse reactions usually occur at the beginning of treatment and gradually subside as the treatment progresses. The characteristics of these adverse reactions are consistent with those commonly seen in GLP - 1 receptor agonists, further demonstrating the safety of Mazdutide. Moreover, Mazdutide is administered via subcutaneous once a week. It uses a user - friendly pen with a design that hides the needle throughout the process. The pre - filled design is disposable, ensuring safety and hygiene. It also adopts a pain - free technology, greatly improving patient compliance and reducing patients' fear and discomfort associated with .
Appropriate Population
As approved by the National Medical Products Administration (NMPA) of China, Mazdutide is indicated for long - term weight control in adult patients on the basis of diet control and increased physical activity. The specific applicable population has an initial body mass index (BMI) as follows: BMI ≥ 28 kg/m² (obesity); or BMI ≥ 24 kg/m² (overweight) with at least one weight - related comorbidity, such as hyperglycemia, hypertension, dyslipidemia, fatty liver, obstructive sleep apnea syndrome, etc.
As an innovative drug, Mazdutide provides a new treatment option for patients with obesity and related metabolic problems. With its unique dual - target mechanism of action, it performs excellently in weight loss and metabolic improvement and has good safety, showing broad application prospects. However, drug treatment should be carried out under the guidance of a doctor, and patients should strictly follow medical advice when using it.
Nigeria
United States
United Kingdom
